Rosacea News August 2010

Rosacea News August 2010

1. Soho, NY. Studio looking for makeup volunteers

I have been contacted by Mana Products to see if an volunteers are interested in a makeup session at the Soho, New York Studio. Please contact Adrienne if you are interested. It looks like their web site is We are working on a new cosmetic line of gentle, effective products to conceal rosacea and other skin flaws and create …

2. Extina, Ketoconazole you can use on your face

A formulation of Ketoconazole 2% for treating seborrheic dermatitis called Extina is currently being promoted by Stiefel Laboratories. Stiefel, which is a part of GSK, is promoting Extina as the “first and only ketoconazole foam for scalp, …

3. V-101 (Oxymetazoline) starting Dose-Finding Trials

Hot on the trail of the Phase 1 Study Results and Funding Announcement is a listing confirming that Vicept Therapeutics are soon to start dose finding trials for the treatment of the redness of rosacea. The trial will study the efficacy of V-101 Cream, applied once per day, at a low dose of 0.01%, 2 lots of mid-dose of 0.06% and 0.1%, …

4. Mediterranean Diet gives you Sun Protection

Thanks to a tip from ClinuvelNews, here is an article in ScienceDaily pointing us to some recent research that shows that a diet rich in antioxidants and omega-3 fatty acids can protect us from skin cancer. In countries like Australia and New Zealand that have high incidences of melanoma, this is some additional reason to follow a diet rich in these nutrients.

5. Vicept Therapeutics positive Phase I study of V-101 for redness of Rosacea

With this latest press release, Vicept Therapeutics is now well and truly out in the public view, and attracting interest from rosacea sufferers. This release of results for Phase I trials of V-101 comes after news that Vicept Therapeutics had secured funding for the development of V-101.

Now that a company name has surfaced we can put the pieces together back to 2007 when Rosacea …

6. Galderma sends Sansrosa backwards – Phase 2 Dosage Trials Again

In yet more proof that Galderma wants to sit on the drug known as Sansrosa, a new August 2010 Phase II dose finding study has been listed at


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s